Sanofi vs Geron Corporation: SG&A Expense Trends

SG&A Expense Trends: Sanofi vs. Geron Corporation

In the ever-evolving pharmaceutical industry, understanding the financial strategies of key players is crucial. Over the past decade, Sanofi and Geron Corporation have demonstrated contrasting trends in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Sanofi's SG&A expenses have consistently hovered around the $10 billion mark, reflecting a stable investment in operational efficiency and market expansion. In contrast, Geron Corporation, a smaller biotech firm, has seen its SG&A expenses grow significantly, from approximately $17 million in 2014 to nearly $69 million in 2023, marking a staggering 300% increase. This growth indicates Geron's aggressive push towards innovation and market presence. As the pharmaceutical landscape continues to shift, these financial strategies highlight the diverse approaches companies take to maintain competitiveness and drive growth.